Ancora Heart Announces Late-Breaking Clinical Science Presentation Among Key Activities at Technology and Heart Failure Therapeutics Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that a late-breaking clinical science presentation featuring the latest data from studies of the investigational AccuCinch^® Ventricular Restoration System will take place at the upcoming Technology and Heart Failure Therapeutics conference (THT 2023). This event is produced by the Cardiovascular Research Foundation (CRF) and will be held March 20 - 22 at the Westin Boston Seaport in Boston, Mass.

The late-breaking clinical science from Ancora Heart will be presented by Dr. Nadira Hamid, interventional echocardiographer, cardiologist at Allina Health Minneapolis Heart Institute and assistant director of the echocardiographic core lab CRF. The data will include complete 12-month clinical outcomes from an analysis of 51 symptomatic heart failure patients with reduced ejection fraction (HFrEF) who were treated with the AccuCinch System.

Below are all the events at THT 2023 where Ancora Heart and the AccuCinch System are included (all times are Eastern Daylight Time):

Late-Breaking Clinical Science: Transcatheter Left Ventricular Restoration in Patients with Heart Failure

• Tuesday, March 21, 2023; 2:50 p.m.; Grand Ballroom A-B Concourse Level, Westin Seaport District
• Presenter: Nadira Hamid, MD, Allina Health Minneapolis Heart Institute and CRF

Device-Based Remodeling as a Therapy for HFrEF: Ancora

• Tuesday, March 21, 2023; 9:45 a.m.; Grand Ballroom A-B Concourse Level, Westin Seaport District
• Presenter: Ulrich P. Jorde, MD, Montefiore Medical Center

Sponsored Satellite Symposium: Transcatheter Restoration of the Dilated LV in Symptomatic HFrEF Patients: The Next Frontier in HF Treatment after GMDT Optimization?

• Monday, March 20, 2023; 12:15-1:30 p.m.; Grand Ballroom A-B Concourse Level, Westin Seaport District

An international heart failure conference organized by the Cardiovascular Research Foundation, THT 2023 is an immersive three-day experience covering the field’s cutting-edge technology and devices, along with innovations in the pipeline.

About the AccuCinch^® Ventricular Restoration System

The AccuCinch System is an investigational device designed to augment the existing care cardiologists provide their heart failure (HF) patients. For patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant.

During the minimally invasive transcatheter AccuCinch System procedure, a flexible implant is attached to the inner wall of the left ventricle and then cinched. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. By directly treating the left ventricle, the AccuCinch System may help reduce symptoms, improve quality of life, and potentially increase life expectancy.

The CORCINCH-HF pivotal trial is underway, designed to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System in patients who have symptomatic heart failure with reduced ejection fraction (HFrEF). (ClinicalTrials.gov Identifier: NCT04331769). This study is being conducted to support the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration.

About Ancora Heart

Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF). The company’s proprietary AccuCinch^® Ventricular Restoration System is the only completely transcatheter device designed to restore the structure and function of the enlarged left ventricle of the heart, thereby addressing the fundamental issue in the progression of heart failure in patients with reduced ejection fraction (HFrEF). Ancora Heart is a privately held company located in Santa Clara, Calif. For more information, please visit www.ancoraheart.com and connect on Twitter (@AncoraHeart), LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005549/en/